Thrombotic microangiopathy during carfilzomib use: case series in Singapore

Blood Cancer J. 2016 Jul 29;6(7):e450. doi: 10.1038/bcj.2016.62.

Authors

Y Chen¹, M Ooi, S F Lim², A Lin², J Lee², C Nagarajan¹, C Phipps¹, Y S Lee¹, N F Grigoropoulos¹, Z Lao¹, S Surendran¹, E M Teh¹, Y T Goh¹, W J Chng², S K Gopalakrishnan¹

Affiliations

¹ Department of Haematology, Singapore General Hospital, Singapore.
² Department of Haematology-Oncology, National University Cancer Institute, Singapore.

No abstract available

Publication types

Case Reports
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Asian People
Female
Humans
Male
Middle Aged
Multiple Myeloma / drug therapy*
Multiple Myeloma / pathology
Oligopeptides / adverse effects*
Oligopeptides / therapeutic use
Singapore
Thrombotic Microangiopathies / chemically induced*
Thrombotic Microangiopathies / pathology

Substances

Oligopeptides
carfilzomib